Drugs / FLOXACILLIN
FLOXACILLIN
also known as
Flucloxacillin · Abboflox · BRL 2039 · Culpen · Floxacillin sodium · Floxacillin sodium anhydrous · Floxapen · FLU · +17 more
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04840641 | Mar → Dec 2021 | — | University of Southern Denmark | Completed | No outcome recorded |
| Phase 1 | NCT00433342 | Mar 2006 → Apr 2020 | chronic kidney disease | Universitaire Ziekenhuizen KU Leuven | Terminated | No outcome recorded |
| Phase 1 | NCT00358371 | Jan → Feb 2005 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT02365493 | Aug 2015 → Oct 2018 | methicillin-resistant staphylococcus aureus infectious disease | Menzies School of Health Research | Terminated | Missed primary |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT06766461 | Jan 2025 → Dec 2026 expected | infectious disease with sepsis | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT02032654 | Aug 2014 → Jul 2017 | cellulitis, erysipelas | Academic Medical Center - University of Amsterdam | Terminated | No outcome recorded |
| Comparator or background therapy15 trials | ||||||
| Phase 2 | NCT05655091 Comparator | Oct 2023 → Dec 2025 overdue | staphylococcus aureus infection | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 2 | NCT00428844 Comparator | Jun 2007 → Mar 2010 | osteomyelitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00303589 Comparator | Dec 2005 → Oct 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05584007 Comparator | Aug 2023 → May 2026 overdue | cellulitis | University of Southampton | Recruiting | No outcome recorded |
| Phase 3 | NCT03176134 Comparator | Jan 2019 → Jul 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02276482 Comparator | Mar 2015 → Sep 2018 | skin disease caused by bacterial infection, skin infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01184872 Comparator | Mar 2010 → Mar 2011 | skin infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04538053 Comparator | Jun 2021 → Dec 2026 expected | infective arthritis, osteomyelitis | Murdoch Childrens Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT03632642 Comparator | Jul → Dec 2019 | staphylococcus aureus infection | The University of Queensland | Withdrawn | No outcome recorded |
| Phase 4 | NCT02922686 Comparator | Dec 2016 → Dec 2019 | abscess, cellulitis, skin infection | Royal College of Surgeons, Ireland | Unknown | No outcome recorded |
| Phase 4 | NCT01876628 Comparator | Oct 2013 → Dec 2015 | cellulitis | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT06454643 Background | Jan 2020 → Jan 2021 | — | Al-Rasheed University College | Completed | Mixed |
| — | NCT02334124 Comparator | Jan 2015 → Jun 2017 | cellulitis | Murdoch Childrens Research Institute | Completed | Met primary |
| — | NCT00405158 Background | Jan 2002 → Mar 2004 | mastitis | Karlstad University | Completed | No outcome recorded |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLOXACILLIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Abboflox | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | BRL 2039 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Culpen | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Floxacillin sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Floxacillin sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Floxapen | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | FLU | “flucloxacillin (FLU) or cefazolin (CZO)” NCT05655091 ↗ |
| Known as | Fluclomix-250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Fluclomix-500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxacilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxacillin | “Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the...” NCT03176134 ↗21“Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.” NCT02276482 ↗ “flucloxacillin, meropenem, and piperacillin/clavulanic acid) in critically ill patients with septic shock.” PMID 40119275 ↗ Mar 2025 “PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin” NCT00303589 ↗ “Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM” NCT05655091 ↗ “Flucloxacillin,” NCT01184872 ↗ |
| Known as | Flucloxacillin sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxacillin sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxacillin sodium monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxacilline | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Flucloxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Galfloxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Ladropen | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | NSC-277175 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Rimaflox | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Stafoxil | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Staphlipen | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Staphylex | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Zoxin 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Known as | Zoxin 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL222645 ↗ |
| Action | Activate | “flucloxacillin activates a receptor (PXR) responsible for transcription of CYP enzymes.” NCT04840641 ↗ |
| Modality | Small molecule | — CHEMBL222645 ↗ |
| Route | Oral | “single oral dose” NCT00358371 ↗ |